When should hydroxyurea be used for children with sickle cell disease?
Mueller
Brigitta U
BU
Baylor College of Medicine, Department of Pediatrics, Texas Children's Sickle Cell Center and Hematology Service, , 6621 Fannin St, CC 1410, Houston, TX 77030, USA. bmueller@bcm.tmc.edu
D000755:Anemia, Sickle Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D000986:Antisickling Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001774:Blood Chemical Analysis; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States
D000986:Antisickling Agents; D006918:Hydroxyurea